Prestige Consumer Healthcare (NYSE:PBH) Issues FY 2027 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) issued an update on its FY 2027 earnings guidance on Thursday. The company provided EPS guidance of 4.550-4.650 for the period, compared to the consensus estimate of 4.580. The company issued revenue guidance of $1.3 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

Prestige Consumer Healthcare Price Performance

Shares of PBH traded up $0.49 during mid-day trading on Friday, reaching $54.92. The company had a trading volume of 597,746 shares, compared to its average volume of 529,217. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.25 and a current ratio of 3.23. Prestige Consumer Healthcare has a 1-year low of $42.62 and a 1-year high of $71.07. The company has a market capitalization of $2.60 billion, a price-to-earnings ratio of 15.38, a P/E/G ratio of 1.69 and a beta of 0.34. The company’s 50 day simple moving average is $48.82 and its 200 day simple moving average is $56.06.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, August 6th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The firm had revenue of $265.71 million during the quarter, compared to the consensus estimate of $250.34 million. During the same period last year, the company earned $0.90 earnings per share. The business’s quarterly revenue was up 6.5% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. Analysts expect that Prestige Consumer Healthcare will post 4.6 EPS for the current year.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Weiss Ratings downgraded Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Canaccord Genuity Group dropped their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research note on Friday, May 15th. Finally, Zacks Research cut Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $70.75.

Key Prestige Consumer Healthcare News

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Adjusted EPS was $0.98, exceeding the $0.89 analyst consensus and rising from $0.95 a year earlier. Revenue increased 6.5% year over year to $265.7 million, above the $250.3 million consensus estimate. Prestige Consumer Healthcare Q1 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Organic sales grew 3.2%, led by the gastrointestinal and dermatological categories, suggesting underlying demand remained resilient despite a challenging consumer environment.
• Positive Sentiment: Prestige raised fiscal 2027 guidance to revenue of $1.290 billion-$1.315 billion, adjusted EPS of $4.55-$4.65, and adjusted free cash flow of at least $270 million. The revenue outlook includes the recently acquired Breathe Right portfolio and LaCorium Health. Prestige Consumer Healthcare Fiscal 2027 First Quarter Results
• Positive Sentiment: Adjusted free cash flow rose to $83.7 million, and management said the cash generation should support deleveraging. The company also extended $400 million of debt maturities to 2034, moving its closest maturity to 2031.
• Neutral Sentiment: An analyst roundup cited a $70.75 price target, indicating potential upside relative to recent trading levels, though price targets reflect individual estimates rather than company guidance. Analysts Set Prestige Consumer Healthcare Price Target
• Negative Sentiment: GAAP diluted EPS fell to $0.61 from $0.95, while net income declined to $29.2 million from $47.5 million. Gross margin also contracted to 51.3% from 56.2%, and acquisition-related expenses and higher interest costs weighed on reported profitability.
• Negative Sentiment: Prestige ended the quarter with approximately $2 billion of net debt, increasing financial leverage and execution risk as it integrates the new acquisitions.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of large investors have recently made changes to their positions in the stock. AQR Capital Management LLC lifted its holdings in Prestige Consumer Healthcare by 11.9% during the 1st quarter. AQR Capital Management LLC now owns 30,056 shares of the company’s stock worth $2,558,000 after purchasing an additional 3,200 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Prestige Consumer Healthcare by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,490 shares of the company’s stock worth $2,535,000 after acquiring an additional 1,289 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Prestige Consumer Healthcare by 28.4% in the first quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after purchasing an additional 120,965 shares during the last quarter. Jane Street Group LLC raised its position in shares of Prestige Consumer Healthcare by 204.0% during the 1st quarter. Jane Street Group LLC now owns 104,802 shares of the company’s stock valued at $9,010,000 after buying an additional 70,330 shares in the last quarter. Finally, Geneos Wealth Management Inc. lifted its stake in Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after purchasing an additional 269 shares during the last quarter. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).